TY  - JOUR
T1  - The Role of Inhibitors SGLT2 in Diabetic Nephropathy; Literature Review
A1  - Sultan Mohammad Allihybi
A1  - Rakan Ayyadah Alshammari
A1  - Basil Ayyadah Alshammari
A1  - Khalid Turki Althobaiti
A1  - Futun Hamed Almufarriji
A1  - Ahmed Yousef Almuqaytib
A1  - Doaa Mohammed Alrebeh
A1  - Zahra Mahdi Almadeh
A1  - Fatimah Ali Alhulw
A1  - Fatimah Ahmed Al Abdrabalnabi
A1  - Noura Shawki Saati
A1  - Barrak Abdullah Alshalawi
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2021
VL  - 12
IS  - 5
DO  - 10.51847/fqUW9tkoS5
SP  - 81
EP  - 84
N2  - Diabetes mellitus is the foremost fons et origo of immedicable kidney disorder all over the world. It is essential to provide glycemic control as well as reduce micro and macrovascular complications, particularly diabetic nephropathy. Inhibitors of co-transporter Sodium-glucose 2 were suggested to provide cardiorenal protection, regardless of glycemic control.  This literature review aims to assess the renal protection of patients with inhibitors of SGLT2 in diabetes mellitus type-2 and the commonly reported adverse effects.  We used the PubMed database and search for relevant articles. We used the following Mesh words: SGLT2 inhibitors, diabetes mellitus Type-2, CKD, Diabetic nephropathy, cardiovascular risk. The use of SGLT2 inhibitors appears to provide cardiorenal protection by certain mechanisms, particularly through albuminuria reduction. Nonetheless, specific adverse effects have been reported, such as increasing the risk of diabetic ketoacidosis, amputation, and genital infection. Caution must be taken to account once an individual started on one of the SGLT-2 inhibitors.
UR  - https://pharmacophorejournal.com/article/the-role-of-inhibitors-sglt2-in-diabetic-nephropathy-literature-review-etj18dux7thanrl
ER  -